Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers

AIMS: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of odanacatib (ODN), a cathepsin K inhibitor, in humans. METHODS: Two double-blind, randomized, placebo-controlled, single oral dose studies were performed with ODN (2–600 mg) in 44 healthy volunteers (36 men and eight...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Stoch, S Aubrey, Zajic, Stefan, Stone, Julie A, Miller, Deborah L, Bortel, Lucas, Lasseter, Kenneth C, Pramanik, Barnali, Cilissen, Caroline, Liu, Qi, Liu, Lida, Scott, Boyd B, Panebianco, Deborah, Ding, Yu, Gottesdiener, Keith, Wagner, John A
التنسيق: Artigo
اللغة:Inglês
منشور في: Blackwell Science Inc 2013
الموضوعات:
Pharmacodynamics
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC3635595/
https://ncbi.nlm.nih.gov/pubmed/23013236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2012.04471.x
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة